Health

Nolotil: a study links nine deaths in Alicante to metamizole, seven of them British patients, and Spain's medicines agency disputes it

Pharmacists at a hospital in Gandía found 41 hospital admissions for agranulocytosis attributed to metamizole in 2016 and 2017. Spain's AEMPS says the study cannot calculate risks. What this reaction is and which signs to watch for.

By · Published · Updated · Sources

Advertisement
Nolotil: a study links nine deaths in Alicante to metamizole, seven of them British patients, and Spain's medicines agency disputes it

Photo: Shixart1985 / Wikimedia Commons · CC BY 2.0

Hands holding a blister pack of pills. Reference photo: Shixart1985 / Wikimedia Commons (CC BY 2.0).

A study presented by pharmacists at the Francesc de Borja Hospital in Gandía (Valencia, Spain) links nine deaths in the province of Alicante to metamizole, the active ingredient in Nolotil, El País and Redacción Médica reported on Monday, November 16.

Seven of those who died were British.

Advertisement

What the study found

The researchers reviewed hospital admissions in 2016 and 2017 in five health departments with many residents from northern Europe: Denia, Villajoyosa, Torrevieja, San Juan and Orihuela. They identified 41 patients hospitalized with agranulocytosis attributed to metamizole: 26 British, 11 Spanish and four of other nationalities.

By their calculations, the risk among British patients was about 120 times higher than among Spaniards when measured by daily doses, and about 79 times higher per treated patient. The work is based on an internal 2019 report by the Valencian regional government that was never published, and it was presented at hospital pharmacy congresses.

The authors point to a possible genetic predisposition, a hypothesis the study did not test, and conclude that metamizole should be avoided in British patients.

The AEMPS response

The Spanish Agency of Medicines (AEMPS) rejects those conclusions. In a reply to El País, it said the report "has significant limitations since it is not analytical but descriptive" and "does not allow incidences or relative risks to be calculated."

What agranulocytosis is and what to watch for

It is a sharp drop in granulocytes, a type of white blood cell that defends the body against infection. It is the best-known serious side effect of metamizole and can be fatal.

Since 2024, the European Medicines Agency (EMA) has asked that anyone taking metamizole stop taking it and seek medical care immediately if they develop fever, chills, sore throat or painful sores in the mouth, nose, throat or genital or anal area.

In Latin America this drug is often sold as dipyrone (dipirona). If you use it often or have doubts, don't self-medicate: talk to your doctor or pharmacist.

Read also: Lo que dice la OMS sobre beber y el cáncer · Reflujo nocturno: la regla de las tres horas

Sources

For information only. It does not replace advice from a health professional. Medical disclaimer

Advertisement